製品番号: HY-B1341

Norethynodrel

(別名: Enidrel; SC-4642; NSC 15432)

Norethynodrel (Enidrel; SC-4642) is an orally active progestogen analog that reduces estrogen-like effects and enhances progestogen-like responses in endometrial stromal cells. Norethynodrel also promotes cell maturation and predecidual cell formation by inducing organelle hyperplasia and glycogen accumulation. Norethynodrel competitively inhibits drug-metabolizing enzymes in rat liver microsomes, thereby prolonging Pentobarbital sleep time, while exhibiting multiple effects including reduced body weight gain, attenuated heart rate elevation and ovulation inhibition. In mouse models, Norethynodrel significantly increases the incidence of mammary adenocarcinoma, cervical cancer and pituitary tumors. Norethynodrel can be used for mechanism research on related diseases such as mammary adenocarcinoma, cervical cancer, ovarian tubular adenoma and pituitary adenoma.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

CAS 番号: 68-23-5
分子式: C₂₀H₂₆O₂
分子量:298.42

保管条件:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Norethynodrel 構造式

CAS 番号: 68-23-5

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性

製品説明

Endogenous Metabolite アイソフォーム固有の製品をすべて表示 :

体外実験

Norethynodrel (10-100 μM; 20 h) weakly inhibits Sprague-Dawley rat hepatic microsomal pentobarbital hydroxylation (K_i=24 μM), aminopyrine N-demethylation, and aniline p-hydroxylation in vitro, with greater inhibition observed at 100 μM than at 10 μM^[3].
Norethynodrel (10-100 μM) acts as a Type I substrate for Sprague-Dawley rat hepatic microsomal cytochrome P-450, exhibiting a spectral dissociation constant (K_s) of 24 μM and a maximum difference absorbance (ΔAmax) of 0.029^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

体内実験

Norethynodrel (125-500 μg/20 g body weight; s.c.; twice weekly; up to 106 weeks) induces a significant increase in mammary gland development, hyperplastic alveolar nodules, type B mammary adenocarcinomas (8 cases), and cervical carcinomas (6 cases) in virgin female A/J mice, while also causing structural changes in ovaries, uteri, and adrenals^[2].
Norethynodrel (10-50 mg/kg; p.o.; single dose) significantly increases pentobarbital-induced sleep duration in male Sprague-Dawley rats, with sleep times of 134 minutes and 221 minutes respectively, indicating inhibition of hepatic pentobarbital metabolism^[3].
Norethynodrel (10-50 mg/kg; p.o.; daily; 4 days) does not induce hepatic microsomal enzymes in male Sprague-Dawley rats, but significantly reduces daily body weight gain^[3].
Norethynodrel (165 μg/kg/day; s.c.; continuous; 20 weeks) contributes a minor, statistically significant attenuation of isoproterenol-induced heart rate increases in female rats at specific time points, with ethinyl estradiol driving the primary attenuation effect^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

A/J Mice (female, virgin, initial weight 15-25 g, spontaneous mammary tumor model)^[2]
Dosage:

500 μg/20 g body weight (weeks 1-2); 250 μg/20 g body weight (weeks 3-5); 125 μg/20 g body weight (remainder up to 106 weeks)
Administration:

s.c.; twice weekly; up to 106 weeks
Result:

Reduced mean body weight throughout treatment compared to controls.
Increased mammary gland development mean score to 3.86.
Induced hyperplastic alveolar nodules (HAN) in over half of treated mice, compared to 1 nodule in controls.
Developed 8 type B mammary adenocarcinomas.
Developed 6 cervical carcinomas.
Caused suppressed ovulation, increased lipid-laden interstitial cells, ceroid pigment deposition, increased mean ovarian weight, and 5 ovarian tubular adenomas in ovaries.
Induced cystic glandular development with endometrial connective tissue hyalinization in uteri, more prominent than in controls.
Caused enlarged zona fasciculata cells with increased lipid content, and ceroid-containing cells at the corticomedullary boundary in all but 2 treated mice in adrenals.
Showed no pituitary cytological alterations or neoplasms.

Animal Model:

Sprague-Dawley (male, 110-180 g)^[3]
Dosage:

10 mg/kg; 50 mg/kg
Administration:

p.o.; daily; 4 days
Result:

Did not alter pentobarbital-induced sleep duration measured 24 hours after the last dose.
Caused no changes in hepatic microsomal protein per gram liver, cytochrome P-450 concentration, or cytochrome P-450 reductase activity.
Significantly decreased daily body weight gain, with weight gain suppressed relative to control rats across the 5-day monitoring period.

Animal Model:

Blue Spruce Farms rats (Sprague-Dawley derived) (female, 260-320 g)^[4]
Dosage:

165 μg/kg/day
Administration:

s.c.; continuous; 20 weeks
Result:

Observed a significant column effect on absolute heart rate at 50 and 60 minutes after isoproterenol administration.
Showed no significant interaction between norethynodrel and ethinyl estradiol throughout the treatment period.
Demonstrated a significant row effect on the change in heart rate from baseline only at 10 minutes post-isoproterenol.
Exhibited a significant interaction between norethynodrel and ethinyl estradiol on change in heart rate from baseline at 10 minutes post-isoproterenol.

化学情報

CAS 番号 68-23-5
性状 Solid
分子量 298.42
分子式 C₂₀H₂₆O₂
Color White to off-white
SMILES

C#C[C@]1(O)CC[C@@]2([H])[C@]3([H])CCC4=C(CCC(C4)=O)[C@@]3([H])CC[C@]12C
別名

Enidrel; SC-4642; NSC 15432
Structure Classification
- Steroids
Initial Source
- Endogenous metabolite
輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶剤 & 溶解度

体外:

DMSO : 1.6 mg/mL (5.36 mM; Need ultrasonic and warming; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.3510 mL

16.7549 mL

33.5098 mL

5 mM

0.6702 mL

3.3510 mL

6.7020 mL

10 mM

---

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (281 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Wienke Jr E C, Cavazos F, Hall D G, et al. Ultrastructural effects of norethynodrel and mestranol on human endometrial stroma cell[J]. American Journal of Obstetrics and Gynecology, 1969, 103(1): 102-111.

[2]. KAHN R H, et al. Effect of long-term treatment with Norethynodrel on A/J and C3H/HeJ mice[J]. Endocrinology, 1969, 84(3): 661-668.

[3]. Freudenthal R I, et al. The effect of norethynodrel, norethindrone and ethynodiol diacetate on hepatic microsomal drug metabolism[J]. Pharmacological Research Communications, 1974, 6(5): 457-468.

[4]. Fregly M J, et al. Response of heart rate to acute administration of isoproterenol in rats treated chronically with norethynodrel, ethinyl estradiol, and both combined[J]. Endocrinology, 1977, 100(1): 148-154.

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.3510 mL	16.7549 mL	33.5098 mL	83.7745 mL
DMSO	5 mM	0.6702 mL	3.3510 mL	6.7020 mL	16.7549 mL

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

Norethynodrel

Endogenous Metabolite アイソフォーム固有の製品をすべて表示